Luteolin is a flavonoid found in celery, parsley, chamomile tea, and several other plant foods, and concentrated supplement forms deliver far more of it than you would get from a normal diet. While luteolin has drawn interest for its anti-inflammatory and antioxidant properties, certain groups of people face real risks from supplementing with it. The biggest concerns center on drug interactions, compounded blood-sugar or blood-pressure lowering, potential interference with cancer treatments, and gastrointestinal side effects. Because nearly all the evidence comes from animal and cell studies rather than large human trials, caution runs in one direction: people with specific health conditions or medication regimens should think carefully before adding luteolin to their routine.
People Taking Medications Processed Through CYP3A4
The most concrete safety concern with luteolin supplements involves the liver enzymes that break down a long list of common medications. Luteolin inhibits CYP3A4, one of the most important drug-metabolizing enzymes in your body. In a study using human liver microsomes, luteolin blocked CYP3A4-driven metabolism of midazolam (a benzodiazepine sedative) in a dose-dependent way.1PubMed. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes CYP3A4 handles the metabolism of roughly half of all prescription drugs, including many statins, calcium channel blockers, immunosuppressants, anti-seizure medications, certain antibiotics, and HIV protease inhibitors. When luteolin slows that enzyme down, more of those drugs stay in your bloodstream for longer, raising both their intended effects and their side effects.
A rat study looking specifically at atorvastatin (a widely used cholesterol drug) drives the point home. When luteolin was given alongside atorvastatin, the peak blood concentration of the statin rose nearly twofold, and overall drug exposure roughly doubled. A nano-formulated version of luteolin designed for better absorption boosted atorvastatin exposure by more than tenfold.2International Journal of Nanomedicine. Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models These are the kinds of shifts that move a drug from its therapeutic range into territory where side effects become likely. While rat metabolism is not identical to human metabolism, the direction and magnitude of these changes are a red flag.
Luteolin also undergoes extensive first-pass metabolism itself, with over 90% cleared within two hours in cultured rat hepatocytes, and it is heavily processed by the UGT1A9 enzyme and taken up through OATP1B1 and OATP1B3 transporters in the liver.3Die Pharmazie – An International Journal of Pharmaceutical Sciences. Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes4Journal of Agricultural and Food Chemistry. Importance of OATP1B1 and 1B3 in the Liver Uptake of Luteolin and Its Consequent Glucuronidation Metabolites Those same OATP transporters are how your liver pulls in drugs like statins, thyroid hormones, and certain cancer medications. Luteolin competing for those transporters could alter how quickly your body clears those drugs. If you take any medication that carries a grapefruit warning on the label, that is a useful proxy: grapefruit inhibits many of the same pathways luteolin does, and the caution applies similarly.
People on Blood Sugar-Lowering Medications
Luteolin lowers blood glucose through several mechanisms in animal studies. In diabetic mice, three weeks of oral luteolin supplementation significantly reduced blood glucose, improved insulin resistance markers, and lowered HbA1c levels.5PubMed. Anti-diabetic effects of luteolin and luteolin-7-O-glucoside on KK-A(y) mice In rats with chemically induced diabetes, luteolin also brought down blood sugar and improved the lipid profile that often accompanies poorly controlled diabetes.6PubMed Central. Evaluation of Antidiabetic Effect of Luteolin in STZ Induced Diabetic Rats: Molecular Docking, Molecular Dynamics, In Vitro and In Vivo Studies These are potentially good properties for people managing blood sugar through diet, but they become a hazard when layered on top of diabetes medications.
The concern gets more specific with acarbose, a drug that works by inhibiting the enzyme alpha-glucosidase to slow carbohydrate digestion. Luteolin also inhibits alpha-glucosidase, and when the two were combined in lab tests, the result was synergistic, meaning the combined effect was greater than either alone would predict.7PubMed. Dietary Flavonoids and Acarbose Synergistically Inhibit α-Glucosidase and Lower Postprandial Blood Glucose In controlled pharmaceutical dosing, synergistic effects can be useful. In unmonitored supplementation stacked on top of a prescription, the same synergy can send blood sugar dangerously low. People taking insulin, sulfonylureas, SGLT2 inhibitors, or any other glucose-lowering drug should be especially cautious, because luteolin could amplify the blood sugar drop without their doctor accounting for it.
People Taking Blood Pressure Medications
A similar stacking risk exists for blood pressure. In spontaneously hypertensive rats, luteolin reduced blood pressure and remodeled thickened blood vessel walls, effects linked to its suppression of the renin-angiotensin-aldosterone system and reduction of a signaling molecule called angiotensin II.8PubMed Central. Luteolin Ameliorates Hypertensive Vascular Remodeling through Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells Separate research found that luteolin delivered directly to a blood-pressure regulation center in the brain lowered blood pressure in hypertensive rats by dampening inflammatory signaling and oxidative stress.9PubMed Central. Luteolin Attenuates Hypertension via Inhibiting NF-κB-Mediated Inflammation and PI3K/Akt Signaling Pathway in the Hypothalamic Paraventricular Nucleus
For someone not on medication, a mild blood-pressure-lowering effect from a supplement might be welcome or neutral. For someone already on ACE inhibitors, ARBs, beta-blockers, or diuretics, the added drop could cause dizziness, fainting, or dangerously low blood pressure, particularly in older adults or anyone prone to orthostatic hypotension (feeling lightheaded when you stand up). Because luteolin appears to act through at least two different blood-pressure pathways, the risk of compounding effects with different classes of antihypertensive drugs is hard to predict without direct clinical data, and that data does not yet exist.
People Undergoing Cancer Treatment
This is where intuition can lead you astray. Luteolin has anti-cancer properties in lab settings, so you might assume it would help alongside chemotherapy. The reality is more complicated. When luteolin was combined with two of the most commonly used pancreatic cancer drugs, 5-fluorouracil and gemcitabine, in cell culture, the anti-proliferative effect was mostly less than additive.10PubMed. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro “Less than additive” means the combination worked worse than you would expect by simply adding the effects of each agent together. In practical terms, the luteolin appeared to blunt the chemotherapy’s effectiveness rather than enhance it.
This finding aligns with a broader pattern seen across various antioxidant supplements during cancer treatment. Antioxidants can protect both healthy and cancerous cells from the oxidative damage that some chemotherapy drugs rely on to kill tumors. While the evidence base here is still largely preclinical, oncologists widely advise against taking concentrated antioxidant supplements during active treatment. Luteolin’s CYP3A4 inhibition adds another layer of risk, since many chemotherapy agents are metabolized through that same enzyme pathway, meaning luteolin could unpredictably alter their blood levels.
People Prone to Nausea and Stomach Problems
Luteolin is a non-selective inhibitor of phosphodiesterase enzymes, including PDE4. That matters because PDE4 inhibition is the same mechanism behind prescription anti-inflammatory drugs like roflumilast (used for COPD), and PDE4 inhibitors are notorious for causing nausea, vomiting, and increased stomach acid secretion. A pharmacological study found that luteolin has a low therapeutic ratio for PDE4, meaning the gap between its anti-inflammatory dose and its gastrointestinal-side-effect dose is narrow.11PubMed. Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia The researchers specifically warned that GI side effects should be monitored whenever luteolin is used in therapeutic doses.
If you have a history of gastritis, acid reflux, peptic ulcers, or inflammatory bowel disease, this is relevant. Concentrated luteolin supplements deliver orders of magnitude more of the compound than you would get from eating celery or chamomile tea, and at those doses the PDE4 inhibition becomes pharmacologically meaningful. People who already take NSAIDs, corticosteroids, or other medications that irritate the stomach lining face compounded GI risk.
People with Hormone-Sensitive Conditions
Luteolin interacts with estrogen signaling in ways that are not entirely straightforward. In MCF-7 breast cancer cells (an estrogen-receptor-positive line), luteolin regulated multiple estrogen signaling pathway genes and cell cycle genes, with effects consistent with anti-estrogenic and anti-proliferative activity.12PubMed Central. Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells Molecular docking studies have also shown that luteolin binds to the estrogen receptor alpha (ER-α), though with weaker affinity than the drug tamoxifen.13Journal of Pharmaceutical and Sciences. Molecular Docking Study of Luteolin and its Derivatives for Identifying Potential ER-α Inhibitors in Breast Cancer
The concern here cuts both ways. For someone with estrogen-receptor-positive breast cancer already on tamoxifen or an aromatase inhibitor, adding a compound that also binds ER-α introduces unpredictable competition at the receptor. It could theoretically enhance the anti-estrogenic effect or, depending on concentration, partially displace the stronger pharmaceutical agent. For people with endometriosis or conditions that respond to hormonal manipulation, the same uncertainty applies. And because luteolin’s hormonal effects may not be purely anti-estrogenic at all doses and in all tissues, anyone with a hormone-sensitive condition should treat concentrated luteolin supplements as a hormonal wildcard rather than a known quantity.
Pregnant Women, Breastfeeding Mothers, and Young Children
There are no human clinical trials evaluating the safety of concentrated luteolin supplements in pregnant or breastfeeding women. This is not unusual for dietary supplements in general, but the lack of safety data is itself the reason for caution. Luteolin’s ability to modulate estrogen signaling, inhibit liver enzymes, and affect blood sugar and blood pressure all represent theoretical risks during pregnancy, when the body is already managing dramatic hormonal and metabolic shifts. The precautionary principle applies: without evidence of safety, concentrated supplementation is not advisable during pregnancy or breastfeeding.
For children, the evidence is thin but not entirely absent. One open-label study gave a luteolin-containing dietary formulation to children with autism spectrum disorders and found reduced levels of inflammatory markers (TNF and IL-6) along with improvements in adaptive behavior scores over the study period.14PubMed Central. Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6 That study was small, lacked a placebo control group, and used a multi-ingredient formulation, so it cannot establish that luteolin alone is safe or effective for children. Pediatric dosing, metabolism rates, and enzyme maturity all differ from adults, and extrapolating adult supplement doses to children is unreliable. Parents considering luteolin for a child should do so only under medical supervision.
The Anticoagulant Question
Given luteolin’s effects on platelet function, a reasonable worry is whether it increases bleeding risk, especially for people on blood thinners like warfarin, apixaban, or clopidogrel. The evidence here is more nuanced than the worry suggests. A mouse study found that luteolin does inhibit a specific platelet activation pathway (GPVI-mediated), which is involved in clot formation triggered by collagen exposure. However, the same study showed that luteolin at the tested dose did not significantly prolong tail bleeding time in mice and had no meaningful effect on standard clotting measures: prothrombin time, activated partial thromboplastin time, thrombin time, or fibrinogen levels.15PubMed Central. Luteolin inhibits GPVI-mediated platelet activation, oxidative stress, and thrombosis
So luteolin appears to have some antiplatelet activity without strongly disrupting normal clotting, at least at the doses tested in mice. The researchers concluded that luteolin does not significantly affect physiological hemostasis. That said, combining even a mild antiplatelet effect with a prescription blood thinner introduces additive risk that has not been tested in humans. And because luteolin inhibits CYP3A4 and potentially other liver enzymes, it could also alter the metabolism of anticoagulant drugs themselves, raising their blood levels. People on anticoagulant or antiplatelet therapy should err on the side of caution until human interaction data exists.
Kidney Disease and an Unexpected Finding
You might expect people with kidney disease to be on the caution list, since impaired kidneys can change how supplements are cleared from the body. But a large observational study of chronic kidney disease patients found that higher dietary luteolin intake was actually associated with lower mortality: each unit increase in luteolin intake was linked to a 27% reduction in all-cause mortality and a 34% reduction in cardiac mortality.16PubMed Central. Dietary intake of luteolin is negatively associated with all-cause and cardiovascular mortality in chronic kidney disease patients These numbers come from an observational design, so they do not prove that luteolin caused the lower mortality; people who eat more luteolin-rich foods may differ in many other ways from those who do not. But the finding at least suggests that luteolin is not overtly harmful to this population at dietary levels.
The crucial distinction, though, is between dietary intake and concentrated supplementation. The range of luteolin intake in that study topped out under 9 milligrams per day, amounts you could plausibly get from food. Many luteolin supplements deliver 50 to 200 milligrams per capsule or more. Kidney disease patients already face altered drug metabolism, electrolyte imbalances, and heightened sensitivity to compounds that affect blood pressure or blood sugar. The observational signal is reassuring for dietary luteolin, but it says nothing about the safety of pharmacological doses in people with reduced kidney function.
The Dietary Versus Supplement Divide
Almost every concern in this article applies to concentrated luteolin supplements, not to luteolin consumed through food. The amount of luteolin in a serving of celery, a cup of chamomile tea, or a handful of fresh parsley is measured in single-digit milligrams, and it arrives alongside fiber, other flavonoids, and the complex matrix of a whole food that slows absorption. Your body has evolved to process flavonoids at these levels without trouble.
Supplements change the equation. They deliver isolated luteolin at concentrations that are tens to hundreds of times higher than what food provides, and newer formulations using nanoparticles or liposomal delivery are designed to overcome the very first-pass metabolism that normally keeps luteolin’s systemic levels low. The atorvastatin interaction study showed dramatically larger drug-interaction effects with a nano-formulated version of luteolin compared to standard luteolin.2International Journal of Nanomedicine. Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models As bioavailability-enhancing technologies improve, the gap between “food-level” and “supplement-level” exposure widens, and so does the potential for harm in vulnerable groups.
What to Tell Your Doctor
If you are considering luteolin supplements and you fall into any of the groups above, the practical step is straightforward: bring the bottle to your next appointment and ask. Many physicians are unfamiliar with luteolin specifically but can quickly assess whether your medications are metabolized through CYP3A4 or whether you have conditions that make additive blood-pressure or blood-sugar effects risky. A pharmacist is often an even better resource for interaction checks, since they work with drug-metabolism pathways daily.
It is also worth noting that the supplement industry does not standardize luteolin products the way pharmaceuticals are standardized. Two bottles labeled “100 mg luteolin” may deliver very different actual doses depending on source plant, extraction method, and added bioavailability enhancers. This variability makes it harder to predict interactions and side effects even when you think you know what you are taking. People with complex medication regimens face the most unpredictability, because even modest enzyme inhibition or blood-pressure shifts can cascade through a carefully balanced prescription stack in ways that neither you nor your doctor planned for.